Boston Scientific Initiates Study Evaluating New Fully Resorbable Scaffold Technology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street set for weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Powerful quake shakes Panama, canal operations normal
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- CoreWeave stock drops on dilution fears and debt concerns
Boston Scientific (BSX) Commences Study of Resorbable Drug-Eluting Scaffold System
July 20, 2015 9:02 AM EDTBoston Scientific (NYSE: BSX) has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation scaffold for the treatment of atherosclerotic coronary lesions.
The first patients in the study were enrolled by Professor Ian Meredith, primary... More



